Oncology drug research and development company Xynomic Pharmaceuticals has acquired exclusive worldwide rights to develop a novel HDAC inhibitor targeting hematological and solid tumors, Abexinostat.
It was previously developed by Abbivie’s subsidiary Pharmacyclics in partnership with Servier, until 2014, when the French Servier left the deal.
Xynomic said that 14 Phase 1 and 2 clinical trials of Abexinostat in US, EU and Asia have already been completed. This shows that Abexinostat is clinically active in multiple tumor settings with a more favorable safety profile among HDAC products.
Xynomic said it will kick off Phase 3 registrational trials worldwide int he second half of 2017.
“We are honored and excited to forge this landmark agreement. We will deploy necessary resources and closely work with KOLs to expeditiously bring this innovative drug to the market to address unmet medical needs,” said Y. Mark Xu, Co-Founder, Chairman and CEO of Xynomic.